Description
The State of Michigan’s Department of Health and Human Services is seeking to negotiate a sole‑source contract with Children’s Hospital Oakland Research Institute (CHORI) to provide confirmatory hemoglobinopathy testing on dried newborn blood spots, including a comprehensive panel of deletions, multiplex ligation‑dependent probe amplification (MLPA), sequencing, and interpretation. The contract will be for a minimum of three years with up to five one‑year renewal options, ensuring continuity of newborn screening follow‑up services. This opportunity is highly specialized, requiring advanced molecular diagnostics that only CHORI currently offers for dried blood spots.
• Scope: Perform confirmatory testing for hemoglobinopathies (α‑ and β‑thalassemia, sickle cell disease, HPFH, etc.) on dried blood spots.
• Required assays: Seven common α‑deletions, α‑CS, α‑MLPA, β‑sequencing, β‑MLPA, HPFH analysis.
• Deliverables: Laboratory results and professional interpretation for each specimen.
• Contract length: Minimum 3 years, with five optional 1‑year extensions (up to 8 years total).
• Funding: Commodity code 94855 – Medical and Laboratory Services (Non‑Physician).
• Sole source justification: CHORI is the only provider capable of performing these specific dried‑blood‑spot assays and interpretations.
• Key dates: Questions due 10/23/2026 3 PM EST; alternative‑source response due 10/28/2026 1:59 PM EST.